Adeno-associated virus-mediated gene transfer of a secreted form of TRAIL inhibits tumor growth and occurrence in an experimental tumor model

✍ Scribed by Jinsang Yoo; Seeyoung Choi; Kyung-Sun Hwang; Won-Kyung Cho; Cho-Rok Jung; Suk-Tae Kwon; Dong-Soo Im

• Publisher: John Wiley and Sons
• Year: 2006
• Tongue: English
• Weight: 297 KB
• Volume: 8
• Category: Article
• ISSN: 1099-498X
• DOI: 10.1002/jgm.832

✦ Synopsis

Abstract

Background

Tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL) induces cell death in various tumor cells, but relatively spares normal cells. Recombinant adeno‐associated virus (rAAV) vectors have a number of advantages including in vivo long‐term gene expression. Here, we assessed the biological activity of a novel, secreted form of TRAIL (sTRAIL) for cancer gene therapy using a rAAV2 vector.

Methods

A plasmid and rAAV2 vectors were constructed encoding sTRAIL composed of a leader sequence, the isoleucine zipper, and the active domain of TRAIL (aa 95–281). The functionality of sTRAIL was validated by cell viability, FACS analysis, caspase‐3 activity, and TUNEL staining. rAAV‐sTRAIL was injected intratumorally to nude mice bearing human A549 lung tumor cells. Nude mice received A549 tumor cells after intravenous delivery of rAAV‐sTRAIL. The antitumor effect was then evaluated by measuring tumor regression and occurrence in the experimental animal.

Results

sTRAIL was released from cells transfected with the sTRAIL expression construct or transduced with rAAV‐sTRAIL, and induced apoptosis in cancer cells, but spared normal fibroblast cells. Secreted sTRAIL formed oligomers including trimers with intersubunit disulfide. Purified sTRAIL exerted much lower cytotoxicity on primary human hepatocytes compared to recombinant TRAIL. Intratumoral delivery of rAAV‐sTRAIL significantly inhibited growth of A549 tumors established in nude mice. A number of apoptotic tumor cells were detected by TUNEL staining in mice treated with rAAV‐sTRAIL. Systemic pretreatment with rAAV‐sTRAIL significantly inhibited tumor formation in nude mice.

Conclusion

The results suggest that rAAV‐sTRAIL may be useful for local or systemic cancer gene therapy for treating TRAIL‐sensitive tumors. Copyright © 2005 John Wiley & Sons, Ltd.